Publications by authors named "G S Figiel"
Altered Mental Status as a Novel Initial Clinical Presentation for COVID-19 Infection in the Elderly.
Am J Geriatr Psychiatry
August 2020
The coronavirus disease of 2019 or COVID-19 was first identified in Hubei Province in China in November of 2019 and quickly spread to become a global pandemic. The virus, SARS-Coronavirus-2, is particularly virulent in the elderly who can develop symptoms and become mortally ill within days of contracting the virus. The virus is easily transmitted by droplets (e.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to see if a home-based physical therapy program could enhance mobility in older adults recovering from hospital stays.
- 22 older adults were involved, with 12 receiving the new therapy and 10 sticking with usual care; results showed significant improvements in walking speed and overall physical performance for the therapy group after 60 days.
- The findings suggest that this therapy is safe and effective, indicating the need for larger studies to further confirm its benefits for older adults.
Long-term safety and tolerability of rivastigmine in patients with Alzheimer's disease switched from donepezil: an open-label extension study.
Prim Care Companion J Clin Psychiatry
August 2012
Objectives: The objective of this article is to present safety and tolerability data from the long-term extension phase of a core study conducted in patients with Alzheimer's disease (AD) who were immediately switched to rivastigmine.
Method: This was a 26-week open-label extension (OLE) of a prospective, 26-week, open-label, single-arm, multicenter study conducted in the United States from October 2003 to January 2005. Patients had a diagnosis of Alzheimer's disease according to DSM-IV-TR and National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria.
Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study.
Prim Care Companion J Clin Psychiatry
August 2012
Objective: Switching patients with Alzheimer's disease from one cholinesterase inhibitor to another represents a viable option for patients not responding to current therapy. The objective of this large U.S.
View Article and Find Full Text PDFBackground: Dementia is frequently associated with behavioral disturbances, some of which have a significant impact on patient quality of life and the likelihood of institutionalization. Cholinergic systems, among other neurotransmitters in the brain, appear to be involved with different behaviors, such as psychosis, depression, agitation, and personality changes.
Scope: This paper reviews the clinical data on the effectiveness of rivastigmine, a dual inhibitor of acetylcholinesterase and butyrylcholinesterase, in ameliorating behavioral disturbances in different patient populations.